Prolonged Viral Shedding of Influenza Virus: Which Definition?

Macé M Schuurmans1 and Nicolas J Mueller2

1Division of Pulmonary Medicine, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland
2Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland

Corresponding author: Macé M Schuurmans, Division of Pulmonary Medicine, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland, Tel: 442554126, E-mail: Macé.Schuurmans@usz.ch


Abstract

Influenza virus infection poses a considerable risk for complications to the general population and in particular to solid organ transplant recipients (SOTR). Life-long immunosuppression in SOTR likely contributes to delayed clearance of influenza virus from the airways: Prolonged Viral Shedding (PVS) has important implications for potential infectivity and infection control measures. Duration of infectivity as measured by viral culture has been reported to last 4-6 days in the non-transplant setting. Shedding measured by Polymerase Chain Reaction (PCR) in immune competent patients is similar, 5-6 days. To date there is no recommended or widely accepted definition of PVS for influenza virus infections. The lack of a PVS definition makes comparisons between studies difficult. Most studies assess shedding duration by serial PCR of nasopharyngeal swabs. A number of studies calculate shedding from the time of onset of symptoms to the last positive detection. Shedding is considered to be “prolonged” if it continues on or beyond day 7 or 14 [7-9]. However, considerable variability exists in defining PVS. A large number of studies rely on two objective measures to define the duration of shedding: This requires at least two positive detections of viral material, usually by PCR. We discuss the different aspects of these definitions and propose a practical definition that takes into account a number of factors relevant to the topic.

Keywords: Influenza virus; Prolonged viral shedding; Diagnosis; Definition; Solid organs transplant recipients

Introduction

Influenza virus infection poses a considerable risk for complications to the general population and in particular to Solid Organ Transplant Recipients (SOTR). Yearly vaccination against influenza virus and early detection and treatment in case of suspected or proven infection are recommended strategies to prevent complications among SOTR [1]. Life-long immunosuppression in SOTR likely contributes to delayed clearance of influenza virus from the airways: Prolonged Viral Shedding (PVS) has important implications for potential infectivity and infection control measures. Preventing nosocomial transmission of influenza virus among SOTR is a concern [1]. Duration of infectivity as measured by viral culture has been reported to last 4-6 days in the non-transplant setting [2]. Shedding measured by Polymerase Chain Reaction (PCR) in immune competent patients is similar, 5-6 days [3-5]. Shedding may extend beyond the symptomatic period. To date there is no recommended or widely accepted definition of PVS for influenza virus infections. The lack of a PVS definition makes comparisons between studies difficult. This is an increasing problem as the body of literature grows in this field of research.

Most studies assess shedding duration by serial PCR of nasopharyngeal swabs. Currently, two main strategies are used to determine duration of shedding. A number of studies calculate shedding from the time of onset of symptoms (OS) to the last positive detection. A correct determination of the end of shedding relies on microbiological detection of virus material whereby the last detection of virus followed by a negative test result defines the end of shedding [6]. Shedding is considered to be “prolonged” if it continues on or beyond day 7 or 14 [7-9]. However, considerable variability exists in defining PVS (Table 1).

Table 1: Selected definitions of prolonged viral shedding for influenza infections.

<table>
<thead>
<tr>
<th>Author, Year, Reference</th>
<th>Cutoff to define PVS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee N, 2009 [16]</td>
<td>≥ 5 days OS</td>
</tr>
<tr>
<td>Gianella M, 2010 [12]</td>
<td>≥7 days VM</td>
</tr>
<tr>
<td>Leekha S, 2007 [14]</td>
<td>≥7 days OS</td>
</tr>
<tr>
<td>Chin BS, 2012 [8]</td>
<td>&gt;7 days OS</td>
</tr>
<tr>
<td>Souza TML, 2010 [7]</td>
<td>&gt;7 days VM</td>
</tr>
<tr>
<td>Carr S, 2011 [9]</td>
<td>≥14 days VM</td>
</tr>
<tr>
<td>Choi SM [13]</td>
<td>&gt;14 days VM</td>
</tr>
</tbody>
</table>

Note: PVS: Prolonged Viral Shedding; OS: Onset of Symptoms; Duration of shedding calculated from the onset of symptoms. VM: Virus Material; Duration of shedding is calculated from first detection of viral material.
may be shorter for SOTR [10,11]. Determining duration of shedding by this way may be considered practical or pragmatic because it considers usual patient behavior and the clinical course.

Using a second strategy, a considerable number of studies rely on two objective measures to define the duration of shedding [7,9,11-13]: This requires at least two positive detections of viral material (VM), usually by PCR. In serial sampling, the first and the last positive detection will define the duration [11]. This method determining the shedding duration may be considered more reliable and objective, and generally would be only feasible in specific settings with regular sampling, such as for SOTR or for research purposes.

For both strategies (OS or VM), the cutoff duration defining PVS must be slightly longer than what is usually considered the normal duration of shedding of influenza virus (5-6 days). Therefore, the definition using 7 days or longer appears to be most appropriate to define PVS.

We propose to use the onset of symptoms as the starting point, and the last positive sample (followed by a negative) as total duration. Prolonged viral shedding starts at day 7. A common definition would allow comparing studies needed for many relevant clinical questions. Following this definition it would make sense to sample one week after OS. The sampling result may also influence the duration of antiviral treatment, as presence of pneumonia, immunosuppression, delayed or absence of antiviral treatment and pediatric age [9,11-13,17]. Many aspects of PVS of influenza virus remain to be determined and having a consensus on what defines PVS may stimulate research and debate in this field. The time is ripe for a consensus definition on PVS from one of the infectious disease societies!

Author contributions

MMS: Concept, data compilation, manuscript preparation and revisions. NJM: Critical manuscript review and revisions.

References